Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2277902
Reference Type
Journal Article
Title
Mechanochemical Endovenous Ablation of Small Saphenous Vein Insufficiency Using the ClariVein (R) Device: One-year Results of a Prospective Series
Author(s)
Boersma, D; van Eekeren, RRJP; Werson, DAB; van Der Waal, RIF; Reijnen, MMJP; de Vries, JPPM
Year
2013
Is Peer Reviewed?
Yes
Journal
European Journal of Vascular and Endovascular Surgery
ISSN:
1078-5884
Volume
45
Issue
3
Page Numbers
299-303
Language
English
PMID
23312507
DOI
10.1016/j.ejvs.2012.12.004
Web of Science Id
WOS:000316778200022
Abstract
OBJECTIVE:
This study evaluated the feasibility, safety and 1-year results of mechanochemical endovenous ablation (MOCA™) of small saphenous vein (SSV) insufficiency.
DESIGN:
Prospective cohort study.
MATERIALS AND METHODS:
Fifty consecutive patients were treated for primary SSV insufficiency with MOCA™ using the ClariVein(®) device and polidocanol. Initial technical success, complications, patient satisfaction and visual analogue scale (VAS) pain score were assessed. Anatomic and clinical success was assessed at 6 weeks and at 1 year.
RESULTS:
Initial technical success of MOCA™ was 100%. At the 6-week assessment, all treated veins were occluded. The 1-year follow-up duplex showed anatomic success in 94% (95% confidence interval, 0.87-1). Venous clinical severity score (VCSS) decreased significantly from 3.0 (interquartile range (IQR) 2-5) before treatment to 1.0 (IQR 1-3, P < 0.001) at 6 weeks and to 1.0 (IQR 1-2, P < 0.001) at 1 year. Median procedural VAS score for pain was 2 (IQR 2-4). No major complications were observed, especially no nerve injury.
CONCLUSIONS:
MOCA™ is a safe, feasible and efficacious technique for treatment of SSV insufficiency. One-year follow-up shows a 94% anatomic success rate and no major complications.
Keywords
Varicose veins; Saphenous vein; Varicose veins therapy; Polidocanol
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity